Skip to main content

Table 4 Comparison of model selection and fit for viral suppression at 96 weeks

From: Comparing the use of aggregate data and various methods of integrating individual patient data to network meta-analysis and its application to first-line ART

Analyses

Model

DIC

pD

Deviance

Between study

prop3

prop4

AgD NMA – Unadjusted

Fixed

111.78

40.95

70.83

0.114 (0.005, 0.325)

6/96

6/96

One-stage IPD-AgD NMA – CD4 + HIV RNA + Male

Fixed

102.45

43.99

58.46

0.077 (0.003, 0.254)

4/96

3/96

One-stage IPD-AgD NMA – CD4 + Male

Fixed

101.17

42.98

58.19

0.085 (0.006, 0.263)

4/96

3/96

One-stage IPD-AgD NMA – CD4 + HIV RNA

Fixed

103.91

43.03

60.88

0.094 (0.005, 0.297)

5/96

3/96

One-stage IPD-AgD NMA – HIV RNA + Male

Fixed

100.66

42.97

57.69

0.072 (0.003, 0.238)

4/96

3/96

One-stage IPD-AgD NMA – CD4

Fixed

103.22

41.91

61.31

0.101 (0.007, 0.296)

4/96

3/96

One-stage IPD-AgD NMA – HIV RNA

Fixed

99.43

42.04

57.39

0.074 (0.004, 0.241)

4/96

3/96

One-stage IPD-AgD NMA – Male

Fixed

101.22

42.02

59.2

0.088 (0.006, 0.275)

4/96

3/96

  1. AgD Aggregate data, IPD Individual patient data, NMA Network meta-analysis, DIC Deviance information criterion, pD Effective number of parameters, prop3 Proportion of observations above deviance2 + leverage = 3, prop4 Proportion of observations above deviance2 + leverage = 4. Between-study heterogeneity obtained through the random-effects model, not the fixed-effect model if it was selected